Markets:

Overview

News

Currencies

International

Treasuries

Seagen Inc. - Common Stock (NQ:SGEN)

N/A UNCHANGED

Last Price Updated: 4:00 PM EST, Dec 13, 2023 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Seagen Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

17 18 Next >

SEAGEN INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Seagen Inc. - SGEN

April 26, 2023

From Kahn Swick & Foti, LLC

Via Business Wire

10 Health Care Stocks With Whale Alerts In Today's Session ↗

April 26, 2023

Via Benzinga

Seagen to Highlight Data From Oncology Portfolio and Pipeline at the 2023 American Society of Clinical Oncology Annual Meeting

April 26, 2023

From Seagen Inc.

Via Business Wire

2 Excellent Dividend Stocks to Buy for Less Than $100 ↗

April 25, 2023

Both companies are steals at current levels.

Via The Motley Fool

Here's How Much You Would Have Made Owning Seagen Stock In The Last 5 Years ↗

April 18, 2023

Via Benzinga

Here's How Much You Would Have Made Owning Seagen Stock In The Last 5 Years ↗

April 03, 2023

Via Benzinga

Analyst Ratings for Seagen ↗

March 24, 2023

Via Benzinga

Second Quarter Outlook For Biotech Stocks ↗

April 25, 2023

Biotech stocks have been consolidating recently but may be ready to rally higher due to factors such as a declining 10-year yield and growing M&A activity.

Via Talk Markets

SGEN Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Seagen Inc. Is Fair to Shareholders

April 24, 2023

From Halper Sadeh LLC

Via Business Wire

3 Low P/E Stocks That Will Double in One Year ↗

April 24, 2023

These are the low-PE stocks to buy and represent companies with strong fundamentals and cash flow potential.

Via InvestorPlace

Hedge Funds Fall Short: Underperforming Low-Cost S&P 500 ETF By 6% In 2023. Here's Why. ↗

April 20, 2023

So far, 2023 has not started well for the hedge fund sector, as a common SPDR S&P 500 Trust ETF (ARCA: SPY) fared much better than the Global X Guru Index ETF (ARCA: GURU), a fund that invests in the...

Via Benzinga

10 Health Care Stocks With Whale Alerts In Today's Session ↗

April 19, 2023

Via Benzinga

This Biotech's Stock Has Been Under Pressure, Could Upcoming Clinical Trials Of Its Nanotechnology-Based COVID Drug Candidate Be The Start Of An Upward March? ↗

April 19, 2023

A company that seems to have seen poor market sentiment lately is NanoViricides Inc. (NYSEAMERICAN: NNVC), a pharmaceutical company specializing in the development of nanomedicine drugs for treating...

Via Benzinga

Tiziana Life Sciences Has Only Fully Human Anti-CD3 mAB In Clinical Studies, Could Be Poised To Improve Care For Patients With Severe Multiple Sclerosis ↗

April 19, 2023

Tiziana Life Sciences (NASDAQ: TLSA), a London-based biotechnology company, is developing a first-in-class drug, Foralumab. Foralumab is the only fully human anti-CD3 monoclonal antibody (mAb) at the...

Via Benzinga

Consider This Undervalued Pharma Giant Before Its Blockbuster Deal Closes ↗

April 17, 2023

Wall Street isn't showing one of pharma's most prominent players any love.

Via The Motley Fool

Seagen to Report First Quarter 2023 Financial Results on April 27, 2023

April 07, 2023

From Seagen Inc.

Via Business Wire

Is Pfizer Stock a Buy, Sell or Hold? Here’s My Call. ↗

April 06, 2023

Pfizer can't depend on Covid-19 vaccines as a revenue source in 2023, but PFE stock can still grow as the drugmaker broadens its pipeline.

Via InvestorPlace

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Univar Solutions Inc. (NYSE - UNVR), Oak Street Health (NYSE – OSH), Seagen Inc. (Nasdaq - SGEN), U.S. Xpress Enterprises, Inc. (NYSE – USX)

April 04, 2023

From Brodsky & Smith LLC

Via GlobeNewswire

FDA Approves Merck's Keytruda Combined With Seagen/Astellas's Padcev For Advanced Urothelial Cancer ↗

April 04, 2023

Via Benzinga

FDA Grants Accelerated Approval for PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Locally Advanced or Metastatic Urothelial Cancer

April 03, 2023

From Seagen Inc.

Via Business Wire

Up 463%, This Sizzling Growth Stock Could Have a Lot More Room to Run ↗

March 29, 2023

Viking Therapeutics stock might in the midst of a historic run.

Via The Motley Fool

It's Not Tesla, Meta Or Nvidia — The Best Performing Large-Cap Stock In 2023 Is A Crypto Play ↗

March 27, 2023

The SPDR S&P 500 ETF Trust (NYSE: SPY) has seen a positive return in 2023. Several sectors are in the green so far this year, and many well-known stocks are among the biggest gainers. Here’s a look at...

Via Benzinga

Merck Germany Regains Exclusive Global Rights To Cancer Drug From Pfizer ↗

March 27, 2023

Via Benzinga

3 Low P/E Stocks That Are Bound to Rebound This Year ↗

March 27, 2023

These are the low P/E stocks to buy at current levels for a sharp reversal rally in the coming quarters.

Via InvestorPlace

Benzinga's Top Ratings Upgrades, Downgrades For March 24, 2023 ↗

March 24, 2023

Via Benzinga

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Oak Street Health (NYSE – OSH), Seagen Inc. (Nasdaq - SGEN), Provention Bio Inc. (Nasdaq - PRVB), Kimball International, Inc. (Nasdaq – KBAL)

March 23, 2023

From Brodsky & Smith LLC

Via GlobeNewswire

Why Pfizer Likely Isn't Done With M&A After the Seagen Deal ↗

March 22, 2023

Pfizer's stock remains down despite its latest dealmaking, but it may only be a matter of time before it starts to rally.

Via The Motley Fool

3 Dividend Contenders to Buy Now for Long-Term Gains Later

March 22, 2023

Dividend stocks have a role to play in any portfolio, and this article highlights three dividend contenders that you can buy now to get long-term gains later

Via MarketBeat

Pfizer Has Another Blockbuster on the Horizon, but That's Not All ↗

March 21, 2023

The drugmaker continues to grab headlines for the right reasons.

Via The Motley Fool

1 Top Healthcare Stock That Could Make You Richer in the Next Decade ↗

March 19, 2023

The Pfizer of tomorrow will be larger and even more lucrative to hold than it is now.

Via The Motley Fool

< Previous 1 2 3 4 5 6 7 8 9

...

17 18 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.